JP2002509104A5 - - Google Patents

Download PDF

Info

Publication number
JP2002509104A5
JP2002509104A5 JP2000539837A JP2000539837A JP2002509104A5 JP 2002509104 A5 JP2002509104 A5 JP 2002509104A5 JP 2000539837 A JP2000539837 A JP 2000539837A JP 2000539837 A JP2000539837 A JP 2000539837A JP 2002509104 A5 JP2002509104 A5 JP 2002509104A5
Authority
JP
Japan
Prior art keywords
composition
magnesium
pills
memantine
dextromethorphan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000539837A
Other languages
English (en)
Japanese (ja)
Other versions
JP4562911B2 (ja
JP2002509104A (ja
Filing date
Publication date
Priority claimed from US09/006,641 external-priority patent/US5952389A/en
Priority claimed from US09/193,892 external-priority patent/US6294583B1/en
Priority claimed from US09/224,829 external-priority patent/US6057373A/en
Application filed filed Critical
Priority claimed from PCT/US1999/000144 external-priority patent/WO1999036064A2/en
Publication of JP2002509104A publication Critical patent/JP2002509104A/ja
Publication of JP2002509104A5 publication Critical patent/JP2002509104A5/ja
Application granted granted Critical
Publication of JP4562911B2 publication Critical patent/JP4562911B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000539837A 1998-01-13 1999-01-13 遅発性ジスキネジア及び他の運動障害の治療方法 Expired - Lifetime JP4562911B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/006,641 1998-01-13
US09/006,641 US5952389A (en) 1998-01-13 1998-01-13 Methods of treating tardive dyskinesia and other movement disorders
US09/193,892 1998-11-18
US09/193,892 US6294583B1 (en) 1998-01-13 1998-11-18 Methods of treating tardive dyskinesia and other movement disorders
US09/224,829 US6057373A (en) 1997-05-22 1999-01-04 Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US09/224,829 1999-01-04
PCT/US1999/000144 WO1999036064A2 (en) 1998-01-13 1999-01-13 Methods of treating tardive dyskinesia and other movement disorders

Publications (3)

Publication Number Publication Date
JP2002509104A JP2002509104A (ja) 2002-03-26
JP2002509104A5 true JP2002509104A5 (https=) 2006-03-09
JP4562911B2 JP4562911B2 (ja) 2010-10-13

Family

ID=27358163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000539837A Expired - Lifetime JP4562911B2 (ja) 1998-01-13 1999-01-13 遅発性ジスキネジア及び他の運動障害の治療方法

Country Status (6)

Country Link
EP (1) EP1047436B1 (https=)
JP (1) JP4562911B2 (https=)
CN (1) CN1293573A (https=)
AU (1) AU765522B2 (https=)
CA (1) CA2318095C (https=)
WO (1) WO1999036064A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
AU6381000A (en) * 1999-07-29 2001-02-19 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
US20050192220A1 (en) * 2001-02-05 2005-09-01 Gevys Pharmaceuticas Ltd. Composition and method for potentiating drugs
AUPR625901A0 (en) * 2001-07-10 2001-08-02 Mcgregor, Neil A method for treatment and/or prophylaxis
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
CA2475763A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
JP4805256B2 (ja) * 2004-05-14 2011-11-02 グリーン・クロス・コーポレイション 右旋性モルヒナンの神経保護特性
WO2006034465A1 (en) * 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
CA2588295C (en) * 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
CN101291663A (zh) * 2005-09-16 2008-10-22 赛诺科学股份公司 预防和治疗睡眠呼吸障碍的方法和工具
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
EP2785337B1 (en) * 2011-12-02 2021-01-20 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
PL3160464T3 (pl) * 2014-06-26 2018-12-31 Contera Pharma Aps 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
CN104188970A (zh) * 2014-08-26 2014-12-10 上海交通大学医学院附属新华医院 右美沙芬在治疗眼睑痉挛或梅杰综合征中的应用
PL4023222T3 (pl) * 2015-09-08 2025-03-24 The Children's Hospital Of Philadelphia Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q
WO2018147792A1 (en) * 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
EP3746062A1 (en) * 2018-01-29 2020-12-09 Pharnext Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
CA3137407A1 (fr) 2019-05-16 2020-11-19 Synapharm Industrial Synthesis Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder
CN115184501A (zh) * 2022-07-20 2022-10-14 中国医学科学院病原生物学研究所 血清代谢物组合筛查在诊断肌张力障碍症中的应用
WO2025167857A1 (zh) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
US4985256A (en) * 1988-04-27 1991-01-15 Bionix Corporation Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5470978A (en) * 1992-11-18 1995-11-28 Eli Lilly And Company Process and intermediates for the preparation of excitatory amino acid receptor antagonists
CZ60697A3 (cs) * 1994-09-02 1998-02-18 Virginia Commonwealth University Farmaceutický prostředek
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists

Similar Documents

Publication Publication Date Title
JP2002509104A5 (https=)
Johnston et al. Action of the neurotoxin kainic acid on high affinity uptake of L‐glutamic acid in rat brain slices
EP0660707B1 (en) Amantadine and related compounds for use in the treatment of peripheral neuropathy
DE69733081T2 (de) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
NZ220631A (en) Pharmaceutical composition containing levodopa methyl ester
AP1665A (en) Tamper-resistant oral opioid agonist formulations.
JP2002539245A5 (https=)
CA2318095A1 (en) Methods of treating tardive dyskinesia and other movement disorders
AU3357800A (en) Method of preparing alkylated salicylamides
EP1392270A2 (en) Abuse resistant pharmaceutical composition containing capsaicin
UA88056C2 (uk) Дозована форма оксикодону, що вводиться один раз на день
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
SK14282000A3 (sk) Farmaceutický prostriedok na liečenie závislosti od alkoholu a drog obsahujúci opiátového antagonistu a modulátor súhrnu nmda receptorov
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
UA76753C2 (uk) Комбінація галантаміну або дезоксипеганіну та протизбуджувального агента, її застосування (варіанти) для лікування наркотичної або токсичної залежності
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
RU99119233A (ru) Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени
BR0013582A (pt) Agonistas retinóides seletivos para rar
BRPI0413883A (pt) composição e método para a administração de um composto farmacologicamente ativo a um mamìfero
IE841048L (en) Anti-seizure medicaments
US3096241A (en) Synergistic antihistamine mixture